What is the new partnership between AstraZeneca and Sun Pharma about?

The partnership between AstraZeneca and Sun Pharma aims to expand access to Sodium Zirconium Cyclosilicate (SZC), an innovative treatment for Hyperkalaemia, across India.

How will the two companies market the Hyperkalaemia treatment?

Under the agreement, AstraZeneca will market the therapy as Lokelma, while Sun Pharma will promote and distribute it as Gimliand.

Why is the treatment for Hyperkalaemia important?

Hyperkalaemia is a clinically significant condition that disproportionately affects patients with chronic kidney disease and heart failure, and the partnership aims to empower healthcare professionals and enhance the quality of life for these patients in India.

Home / Business and Economy / AstraZeneca and Sun Pharma Expand Access to Hyperkalaemia Treatment Across India

AstraZeneca and Sun Pharma Expand Access to Hyperkalaemia Treatment Across India

17 Nov

•

Summary

AstraZeneca and Sun Pharma sign second brand partnership for Sodium Zirconium Cyclosilicate
Aim to accelerate availability of innovative treatment for Hyperkalaemia to more patients
AstraZeneca to market therapy as Lokelma, Sun Pharma to promote it as Gimliand

AstraZeneca and Sun Pharma Expand Access to Hyperkalaemia Treatment Across India

In a significant development on November 17, 2025, AstraZeneca Pharma India and Sun Pharmaceutical Industries have entered into a second brand partnership to accelerate the availability of Sodium Zirconium Cyclosilicate (SZC), an innovative and highly effective treatment for Hyperkalaemia, to patients across India.

Under the agreement, both companies will jointly promote, market, and distribute the therapy, with AstraZeneca marketing it as Lokelma and Sun Pharma promoting it as Gimliand. This collaboration aims to significantly expand the reach of this vital treatment and help address the growing burden of Hyperkalaemia in the country.

Hyperkalaemia is a serious condition that disproportionately affects patients with chronic kidney disease and heart failure. The partnership between the two pharmaceutical giants is a significant step in empowering healthcare professionals and enhancing the quality of life for patients suffering from this condition in India.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.